Trial Profile
A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults With Relapsed and Refractory Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Antineoplastics; Clofarabine
- Indications Acute biphenotypic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacogenomic
- 01 Nov 2021 Results published in the Leukemia Research
- 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.